Reported Earlier, Nanobiotix Reports Updated Phase 1 Data Showing JNJ-1900 (NBTXR3) Plus Anti-PD-1 Achieves 37% ORR And 63% DCR In Naïve R/M-HNSCC Patients

Author: Benzinga Newsdesk | September 30, 2025 02:40am

• Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1
• 63% (26/41) disease control rate ("DCR") and 37% (15/41) objective response rate ("ORR") in evaluable anti-PD-1 naïve patients per RECIST 1.1
• 74% (37/50) DCR and 32% (16/50) ORR in evaluable anti-PD-1 resistant patients per RECIST 1.1
• 15.5 months median Overall Survival ("mOS") in evaluable anti-PD-1 naïve patients
• 11.4 months mOS in evaluable anti-PD-1 resistant patients
• Investigators concluded that these promising results warrant further exploration in randomized controlled trials

Data presented as a "Top-rated Abstract in Head and Neck Cancer" at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th

Posted In: NBTX